Company intelligence / Profile preview

Phoenix Solutions AS

Oslo, Oslo, Norwayphoenixsolutionsco.com ↗

Ownership: Private
Development stage: Other

Overview

The company has initiated its first-in-human clinical trial of ACT®, combining the platform with chemotherapy to treat hepatic metastases from colorectal and pancreatic cancers. Early pre-clinical data showed improved efficacy of various therapeutic molecules using this approach. Clinical sites include The Institute of Cancer Research London and Royal Marsden NHS Foundation Trust; additional sites planned in Norway.

Therapeutic areas: Oncology
Modalities: Microbubble/microdroplet formulation for ultrasound-mediated drug delivery ("Acoustic Cluster Therapy" or ACT®)Drug delivery enhancement for small molecules and nano-drugs
Industry: Biotech

Partnerships

GE HealthcareThe Institute of Cancer Research London & Royal Marsden NHS Foundation TrustNorwegian University of Science and Technology

Beyond the preview

Go deeper on Phoenix Solutions AS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix Solutions AS.

Explore the full profile